Tokyo - Delayed Quote
JPY
AnGes, Inc. (4563.T)
27.00
-2.00
(-6.90%)
At close: 3:30:00 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Ei Yamada M.D., Ph.D.
|
CEO, President & Representative Director | -- | -- | 1950 |
|
Yuka Murakami
|
Accounting Department Manager | -- | -- | -- |
|
Mr. Naoya Sato
|
Director of Administration & Director | -- | -- | 1960 |
AnGes, Inc.
Saito Bio-Incubator
7-7-15, Saito-asagi 7-7-15, Saito-asagi
Ibaraki, 567-0085
Japan
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 56
Description
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
Corporate Governance
AnGes, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 6, 2026 at 6:30 AM UTC
AnGes, Inc. Earnings Date
Recent Events
Recent Events Information Not Available
